Core Laboratories Inc.

As of June 30, 2026, Core Laboratories Inc. carries a market capitalization of 534.55M, placing it among publicly traded companies globally. Its enterprise value stands at 683.03M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Core Laboratories Inc.'s next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, Core Laboratories Inc. has 45.88M shares outstanding.

As of June 30, 2026, Core Laboratories Inc. trades at a trailing price-to-earnings ratio of 21.82. The price-to-sales ratio is 1.02, and the price-to-book ratio stands at 1.96.

As of June 30, 2026, Core Laboratories Inc. trades at an EV/EBITDA multiple of 10.90 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.32 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 14.29 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Core Laboratories Inc. trades at an EV/FCF ratio of 19.19, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 683.03M versus a market cap of 534.55M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Core Laboratories Inc. maintains a current ratio of 2.12, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 59.23, indicating elevated leverage, while an interest coverage ratio of 5.70 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Core Laboratories Inc. posted a return on equity (ROE) of 9.12, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.19 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.10, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.06, useful for judging operating efficiency across full business cycles. The company generates approximately 154,979.70 in revenue per employee across its workforce of 3,350.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 7.35 indicates how many times Core Laboratories Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Core Laboratories Inc. recorded 12.10M in income tax expense. That works out to an effective tax rate of 32.89, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 36.80M, leaving 24.35M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Core Laboratories Inc.'s stock has declined approximately 26.39% over the past 52 weeks. The 50-day moving average sits at 11.25, while the 200-day moving average is 14.12.

Over the twelve months ended June 30, 2026, Core Laboratories Inc. generated 519.18M in revenue and converted that into 24.35M in net income, yielding earnings per share of 0.53. EBITDA reached 62.65M, while operating income came in at 41.11M.

As of June 30, 2026, Core Laboratories Inc. holds 22.74M in cash and equivalents against 165.12M in total debt, resulting in a net debt position of 91.13M. Total book value stands at 272.67M, with working capital of 113.31M providing operational flexibility.

Core Laboratories Inc. produced 28.22M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Core Laboratories Inc. posted a gross margin of 16.66, reflecting its pricing power and cost economics. The operating margin of 7.92 and net profit margin of 4.69 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Core Laboratories Inc. paid dividends of 0.04 per share. The dividend payout ratio of 7.39 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 5.19, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 5.24, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Core Laboratories Inc. shareholders.

Core Laboratories Inc.'s most recent stock split took place on July 9, 2010 with a 1:2 split ratio.

As of June 30, 2026, Core Laboratories Inc. has an Altman Z-Score of 3.23, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.